Clinical
Indications |
|
Chromogranin
A is produced by a variety of normal and malignant
neuroendocrine and sympathetic neuronal cells and may serve as
a clinically useful marker for hormone-negative endocrine
neoplasia.
Elevated levels of Chromogranin A
are seen in neuroendocrine tumours, including
phaeochromocytoma, medullary carcinoma of thyroid, pancreatic
islet cell adenoma, carcinoid tumour, anterior pituitary
adenoma, carotid body tumour, small cell carcinoma of the lung
and neuroblastoma.
Minor increases are seen in essential hypertension.
Chromogranin A concentrations rise markedly in patients with
renal failure.
|